Erratum: Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (Leukemia (2015) 29 (1092-1103) 10.1038/leu.2014.331);Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells

Leukemia

Volumn 29, Issue 5, 2015, Pages 1092-1103

  Dolatshad, H ^a   Pellagatti, A ^a   Fernandez Mercado, M ^a   Yip, B H ^a   Malcovati, L ^b,c   Attwood, M ^a   Przychodzen, B ^d   Sahgal, N ^e   Kanapin, A A ^a   Lockstone, H ^e   Scifo, L ^a   Vandenberghe, P ^f   Papaemmanuil, E ^g   Smith, C W J ^a   Campbell, P J ^g   Ogawa, S ^h   Maciejewski, J P ^d   Cazzola, M ^b,c   Savage, K I ⁱ   Boultwood, J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^h GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCLAF1 PROTEIN; BRCA1 PROTEIN; CBL PROTEIN; CD34 ANTIGEN; IRON; SF3B1 PROTEIN; TRANSCRIPTOME; TUMOR PROTEIN; UNCLASSIFIED DRUG; PHOSPHOPROTEIN; RNA; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ARTICLE; BONE MARROW CULTURE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; DNA DAMAGE; EXON; GENE DISRUPTION; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MUTANT; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; RNA PROCESSING; RNA SEQUENCE; RNA SPLICING; WILD TYPE; ALTERNATIVE RNA SPLICING; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; HOMEOSTASIS; K562 CELL LINE; MALE; METABOLISM; MUTATION; POINT MUTATION; REFRACTORY ANEMIA WITH EXCESS BLASTS; SEQUENCE ANALYSIS; STEM CELL;

ALTERNATIVE SPLICING; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIGENS, CD34; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEMATOPOIETIC STEM CELLS; HETEROZYGOTE; HOMEOSTASIS; HUMANS; K562 CELLS; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; POINT MUTATION; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA; RNA SPLICING; SEQUENCE ANALYSIS, RNA; STEM CELLS;

EID: 84929277822     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.178     Document Type: Erratum

References (47)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
2. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
3. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
4. Boultwood J, Dolatshad H, Varanasi SS, Yip BH, Pellagatti A. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv Biol Regul 2014; 54: 153-161.
5. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
6. Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer 2013; 133: 260-265.
7. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
8. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C et al. Clinical signifi cance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
9. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
10. Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101: 1996-2000.
11. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120: 3173-3186.
12. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012; 26: 1137-1140.
13. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
14. Matsunawa M, Yamamoto R, Sanada M, Sato-Otsubo A, Shiozawa Y, Yoshida K et al. Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia 2014; 28: 1844-1850.
15. Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M et al. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood 2014; 123: 3336-3343.
16. Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A, Germing U, Lamikanra AA et al. Effects of L-leucine in 5q- syndrome and other RPS14-de ficient erythroblasts. Leukemia 2012; 26: 2154-2158.
17. Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013; 27: 889-896.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
19. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-764.
20. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006; 108: 337-345.
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
22. Gandoura S, Weiss E, Rautou PE, Fasseu M, Gustot T, Lemoine F et al. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol 2013; 58: 936-948.
23. Wang E, Aslanzadeh V, Papa F, Zhu H, de la Grange P, Cambi F. Global profiling of alternative splicing events and gene expression regulated by hnRNPH/F. PLoS One 2012; 7: e51266.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
25. Corrionero A, Minana B, Valcarcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 2011; 25: 445-459.
26. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140.
28. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNAseq data. Genome Res 2012; 22: 2008-2017.
29. Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3: e1970.
30. Tan JS, Mohandas N, Conboy JG. High frequency of alternative first exons in erythroid genes suggests a critical role in regulating gene function. Blood 2006; 107: 2557-2561.
31. Tucker EJ, Wanschers BF, Szklarczyk R, Mountford HS, Wijeyeratne XW, van den Brand MA et al. Mutations in the UQCC1-interacting protein, UQCC2, cause human complex III deficiency associated with perturbed cytochrome b protein expression. PLoS Genet 2013; 9: e1004034.
32. Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013; 3: 1122-1129.
33. Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ et al. Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell 2014; 54: 445-459.
34. Pacheco TR, Moita LF, Gomes AQ, Hacohen N, Carmo-Fonseca M. RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts. Mol Biol Cell 2006; 17: 4187-4199.
35. Bargou RC, Wagener C, Bommert K, Arnold W, Daniel PT, Mapara MY et al. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J Exp Med 1996; 183: 1205-1213.
36. Zhang R, Misra V. Effects of cyclic AMP response element binding protein- Zhangfei (CREBZF) on the unfolded protein response and cell growth are exerted through the tumor suppressor p53. Cell Cycle 2014; 13: 279-292.
37. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
38. Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia 2015; 29: 188-195.
39. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440: 96-100.
40. Cazzola M, Invernizzi R. Ring sideroblasts and sideroblastic anemias. Haematologica 2011; 96: 789-792.
41. Moriguchi T, Yamamoto M. A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation. Int J Hematol 2014; 100: 417-424.
42. Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013; 123: 4627-4640.
43. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA doublestrand breaks. Nature 2009; 462: 935-939.
44. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462: 886-890.
45. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013; 122: 999-1006.
46. Kurtovic-Kozaric A, Przychodzen B, Singh J, Konarska MM, Clemente MJ, Otrock ZK et al. PRPF8 defects cause missplicing in myeloid malignancies. Leukemia 2015; 29: 126-136.
47. Keightley MC, Crowhurst MO, Layton JE, Beilharz T, Markmiller S, Varma S et al. In vivo mutation of pre-mRNA processing factor 8 (Prpf8) affects transcript splicing, cell survival and myeloid differentiation. FEBS Lett 2013; 587: 2150-2157.